@article{d95000587baf4c0bb6d8493ca791bca8,
title = "A vaccine targeting the L9 epitope of the malaria circumsporozoite protein confers protection from blood-stage infection in a mouse challenge model",
abstract = "Pre-erythrocytic malaria vaccines that induce high-titer, durable antibody responses can potentially provide protection from infection. Here, we engineered a virus-like particle (VLP)-based vaccine targeting a recently described vulnerable epitope at the N-terminus of the central repeat region of the Plasmodium falciparum circumsporozoite protein that is recognized by the potently inhibitory monoclonal antibody L9 and show that immunization with L9 VLPs induces strong antibody responses that provide protection from blood-stage malaria in a mouse infection model.",
author = "Lucie Jel{\'i}nkov{\'a} and Yevel Flores-Garcia and Sarah Shapiro and Roberts, {Bryce T.} and Nikolai Petrovsky and Fidel Zavala and Bryce Chackerian",
note = "Funding Information: This study was supported, in part, by a generous contribution to the UNM Foundation in honor of Jeffrey Michael Gorvetzian in support of biomedical research excellence at the University of New Mexico School of Medicine and by T32-AI007538 (to L.J.). F.Z. thanks the Bloomberg Philanthropies for continued support. Development of Advax adjuvants was supported by funding from National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Contracts HHS-N272201400053C, HHS-N272200800039C and U01-AI061142. Publisher Copyright: {\textcopyright} 2022, The Author(s).",
year = "2022",
month = dec,
doi = "10.1038/s41541-022-00457-1",
language = "English (US)",
volume = "7",
journal = "npj Vaccines",
issn = "2059-0105",
publisher = "Nature Publishing Group",
number = "1",
}